Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients.

Antimicrobial Agents and Chemotherapy
K E N Milne, I M Gould

Abstract

Stenotrophomonas maltophilia is increasingly being isolated from the respiratory tract of individuals with cystic fibrosis, and, because of its multidrug-resistant nature, the selection of suitable treatment regimens can be problematical. Etest methodology was used to facilitate MIC and antimicrobial combination testing on 80 isolates of S. maltophilia cultured from the respiratory tract of Scottish individuals with cystic fibrosis between 2001 and 2010. The overall rate of susceptibility for the 1,410 MIC tests was 23.1%, and resistance was 68.9%. The most active antimicrobials were minocycline, co-trimoxazole, and doxycycline, with 92.4%, 87.3%, and 58.8% of isolates being susceptible, respectively. Of the 517 combinations, 13.2% were synergistic, with the most synergistic being ticarcillin/clavulanate plus aztreonam (91.7% synergistic), ticarcillin/clavulanate plus colistin (40%), and ticarcillin/clavulanate plus levofloxacin (19.4%). Colistin plus tobramycin was the only antagonistic combination (0.2%). By the median susceptible breakpoint index, the most active combinations were minocycline plus co-trimoxazole (median index, 20), minocycline plus piperacillin-tazobactam (median, 20), and co-trimoxazole plus ceftazidime (me...Continue Reading

References

Jan 11, 2000·The Journal of Antimicrobial Chemotherapy·G BonfiglioS Stefani
Apr 17, 2001·Antimicrobial Agents and Chemotherapy·S ValdezateR Cantón
Nov 1, 2001·Diagnostic Microbiology and Infectious Disease·T S KruegerD E Nix
Aug 3, 2002·American Journal of Respiratory and Critical Care Medicine·Christopher H GossGordon D Rubenfeld
Dec 21, 2002·Diagnostic Microbiology and Infectious Disease·Evangelos J Giamarellos-BourboulisHelen Giamarellou
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds
Oct 10, 2003·Current Opinion in Pulmonary Medicine·Robert N Chernish, Shawn D Aaron
Jan 24, 2004·The European Respiratory Journal·V MarchacA Bush
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·F M MacKenzieI M Gould
Nov 18, 2005·Lancet·F M MacKenzieI M Gould
Nov 14, 2006·Current Opinion in Pediatrics·Steven M Rowe, John P Clancy
Mar 28, 2007·Thorax·Christopher H Goss, Jane L Burns
Aug 30, 2008·Journal of the Royal Society of Medicine·J Stuart Elborn
Nov 28, 2008·Current Opinion in Biotechnology·Michael N DudleyDavid C Griffith
Dec 19, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Samuel M MoskowitzGarry R Cutting
Oct 17, 2009·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Edith T ZemanickFrank J Accurso
Apr 9, 2010·Clinical Microbiology Reviews·John J Lipuma
Jun 15, 2010·Diagnostic Microbiology and Infectious Disease·George A Pankey, Deborah S Ashcraft
Aug 19, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Valerie WatersFelix Ratjen

❮ Previous
Next ❯

Citations

May 2, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J W BettsD W Wareham
Nov 23, 2013·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Razan HamoudMichael Wink
Aug 24, 2013·Expert Review of Respiratory Medicine·G McCaugheyMichael M Tunney
Dec 3, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN Chinese XDR Consensus Working GroupC Zhuo
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D van DuinUNKNOWN AST Infectious Diseases Community of Practice
Jan 18, 2018·Mycopathologia·Rui KanoHiroshi Kamata
Sep 7, 2013·Journal of the International AIDS Society·Iris UsachJosé-Esteban Peris
Dec 3, 2016·Journal of Medical Microbiology·Angel Manjarrez-HernandezRigoberto Hernandez-Castro
Feb 28, 2018·Journal of Medical Microbiology·Duaa W Al-SadeqGheyath K Nasrallah
Oct 6, 2017·The Cochrane Database of Systematic Reviews·Valerie Waters, Felix Ratjen
Dec 4, 2019·Diagnostic Microbiology and Infectious Disease·Shane B PattersonUNKNOWN IDCRP TIDOS Group
Jun 10, 2021·Zeitschrift Für Naturforschung. C, a Journal of Biosciences·Abdi Wira SeptamaAmit Jaisi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.